Similar articles

• A SPECIAL MEETING REVIEW EDITION: Highlights in Hepatitis C Virus From the 2017 AASLD Liver Meeting: A Review of Selected Presentations From the 2017 AASLD Liver Meeting • October 20-24, 2017 • Washington, DCSpecial Reporting on:• Efficacy, Safety, and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis• Hepatitis C Virus Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Participants on Opiate Agonist Therapy: Co-STAR Part B• Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis• SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study• Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-Infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program• The C-BREEZE 1 and 2 Studies: Efficacy and Safety of Ruzasvir Plus Uprifosbuvir for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection100% SVR With 8 Weeks of Ledipasvir/Sofosbuvir in HIV-Infected Men With Acute HCV Infection: Results From the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1-Infected Individuals)PLUS Meeting Abstract SummariesWith Expert Commentary by:Fred Poordad, MDChief, HepatologyUniversity Transplant CenterClinical Professor of MedicineThe University of Texas Health, San AntonioSan Antonio, Texas.

  [No authors listed] [No authors listed] Gastroenterol Hepatol (N Y). 2017 Dec;13(12 Suppl 5):1-24. Gastroenterol Hepatol (N Y). 2017. PMID: 29950953 Free PMC article. No abstract available.
• Commentary on: "Satisfaction with information used to choose prostate cancer treatment." Gilbert SM, Sanda MG, Dunn RL, Greenfield TK, Hembroff L, Klein E, Saigal CS, Pisters L, Michalski J, Sandler HM, Litwin MS, Wei JT. H. Lee Moffitt Cancer Center, Tampa, Florida; Department of Urology, Emory University, Atlanta, Georgia; Department of Urology, University of Michigan, Ann Arbor, Michigan; Department of Psychiatry and Public Health Institute, University of California-San Francisco, California; Institute for Public Policy and Social Research, Michigan State University, Lansing, Michigan; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio; Department of Urology and Department of Health Policy and Management, University of California-Los Angeles, Los Angeles, California; Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri; Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.: J Urol 2014;191(5):1265-71. doi:10.1016/j.juro.2013.12.008. [Epub 2013 Dec 12].

  Brent H. Brent H. Urol Oncol. 2016 May;34(5):247-8. doi: 10.1016/j.urolonc.2015.02.015. Epub 2015 May 16. Urol Oncol. 2016. PMID: 25990613
• Healthcare update ... Cedars-Sinai Medical Center.

  de Lafuente D. de Lafuente D. Mod Healthc. 1993 Aug 9;23(32):42. Mod Healthc. 1993. PMID: 10127617 No abstract available.
• Alimentary tract cytopathology in human immunodeficiency virus infection: a review of experience in Los Angeles.

  Strigle SM, Gal AA, Martin SE. Strigle SM, et al. Diagn Cytopathol. 1990;6(6):409-20. doi: 10.1002/dc.2840060606. Diagn Cytopathol. 1990. PMID: 2292226 Review.
• Digestive Disease Week 2000 conference report: New treatments for chronic hepatitis C.

  Brown PJ, Neuman MG. Brown PJ, et al. Can J Clin Pharmacol. 2001 Summer;8(2):67-71. Can J Clin Pharmacol. 2001. PMID: 11493933 Review.